Skip to main content
SpringerLink
Log in

Pharmacological Treatment of Vascular Dementia

  • Chapter
Vascular Dementia

Part of the book series: Current Clinical Neurology ((CCNEU))

  • 1620 Accesses

Abstract

Disease expression in vascular dementia (VaD) is heterogeneous and provides several potential targets for treatment, including (1) symptomatic improvement of the core symptoms (cognition, function, and behavior), (2) slowing of progression, and (3) treatment of secondary manifestation that affect cognition (e.g., depression, anxiety, and agitation) (1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rockwood K, Gauthier S, Erkinjuntti T. Prevention and treatment of vascular dementia. In: Erkinjuntti T, Gauthier S, eds. Vascular Cognitive Impairment. London, UK: Martin Duniz Ltd, 2002, pp. 587–595.

    Google Scholar 

  2. Sawada T, Whitehouse PJ. Regulatory guidelines for antidementia drugs. In: Erkinjuntti T, Gauthier S, eds. Vascular Cognitive Impairment. London, UK: Martin Duniz Ltd, 2002, pp. 619–627.

    Google Scholar 

  3. Ferris S, Gauthier S. Cognitive outcome measures in vascular dementia. In: Erkinjuntii T, Gauthier S, eds. Vascular Cognitive Impairment. London, UK: Martin Duniz Ltd, 2002, pp. 395–400.

    Google Scholar 

  4. Quinn J, Moore M, Benson DF, et al. A videotaped CIBIC for dementia patients: validity and reliability in simulated clinical trial. Neurology 2002;58(3):433–437.

    PubMed  CAS  Google Scholar 

  5. Orgogozo J-M., Rigaud A-S., Stoffler A, Mobius H-J, Forette F. Efficacy and safety of Memantine in patients with mild to moderate vascular dementia. A randomized, placebo-controlled trial (MMM 300). Stroke 2002;33:1834–1839.

    Article  PubMed  CAS  Google Scholar 

  6. Royall D, Roman G. Executive control function: a rational basis for the diagnosis of vascular dementia. Alzheimer Dis Assoc Disord 1999;13(Suppl 3):69–80.

    Google Scholar 

  7. Royall DR. Executive cognitive impairment: a novel perspective on dementia. Neuroepidemiology 2000;19:293–299.

    Article  PubMed  CAS  Google Scholar 

  8. Pohjasvaara T, Leskela M, Vataja R, et al. Post-stroke depression, executive dysfunction and functional outcome. Eur J Neurol 2002;9:269–275.

    Article  PubMed  CAS  Google Scholar 

  9. Chui E, Yastrubetskaya O, Williams M. Pharmacotherapy of mood and behavior symptoms. In: Erkinjuntti T, Gauthier S, eds. Vascular Cognitive Impairment. London, UK: Martin Duniz Ltd., 2002, pp. 597–605.

    Google Scholar 

  10. Gauthier S, Gelinas I. Evaluation of daily activities in vascular cognitive impairment. In: Erkinjuntti T, Gauthier S, eds. Vascular Cognitive Impairment. London, UK: Martin Duniz Ltd., 2002, pp. 411–416.

    Google Scholar 

  11. Walsh AC, Walsh BH, Melaney C. Senile-presenile dementia: follow-up data on an effective psychotherapy-anticoagulant regimen. J Am Geriatr Soc 1978;26:467–470.

    PubMed  CAS  Google Scholar 

  12. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154–1166.

    PubMed  CAS  Google Scholar 

  13. Erkinjuntti T, Rockwood K. Vascular cognitive impairment. Psychogeriatrics 2001;l:27–38.

    Article  Google Scholar 

  14. Erkinjuntti T. Cerebrovascular dementia. Pathophysiology, diagnosis and treatment. CNS Drugs 1999;12:35–48.

    Article  Google Scholar 

  15. Inzitari D, Lamassa M, Pantoni L. Treatment of vascular dementias. In: Bowler JV, Hachinski V, eds. Vascular Cognitive Impairment Preventable Dementia. Oxford, UK: Oxford University Press, Oxford, 2003, pp. 277–292.

    Google Scholar 

  16. Rother M, Erkinjuntti T, Roessner M, Kittner B, Marcusson I, Karlsson I. Propentofylline in the treatment of Alzheimer’s disease and vascular dementia. Dementia Geriatr Cogn Disord 1998;9(Suppl 1):36–43.

    Article  CAS  Google Scholar 

  17. Pantoni L, Carosi M, Amigoni S, Mascalchi M, Inzitari D. A preliminary open trial with nimodipine in patients with cognitive impairment and leukoaraiosis. Clin Neuropharmacol 1996;19:497–506.

    PubMed  CAS  Google Scholar 

  18. Mielke R, Moller H-J, Erkinjunti T, Rosenkranz B, Rother M, Kittner B. Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials. Alzheimer Dis Assoc Disord 1998;12(Suppl 2):29–35.

    Google Scholar 

  19. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Work Group. Neurology 1993;43:250–260.

    PubMed  CAS  Google Scholar 

  20. Pischel T. Long-term-efficacy and safety of propentofylline in patients with vascular dementia. Results of a 12-month placebo-controlled trial [abstract]. Neurobiol Aging 1998;19(Suppl):S182.

    Google Scholar 

  21. Pantoni L, Rossi R, Inzitari D, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian multi-infarct dementia trial. J Neurol Sci 2000;175:124–134.

    Article  PubMed  CAS  Google Scholar 

  22. Pantoni L, Bianchi C, Beneke M, Inzitari D, Wallin A, Erkinjunti T. The Scandinavian multi-infarct dementia trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. J Neurol Sci 2000,175:116–123.

    Article  PubMed  CAS  Google Scholar 

  23. Erkinjuntti T, Inzitari D, Pantoni L, et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm 2000;59(Suppl):23–30.

    CAS  Google Scholar 

  24. Lopez-Arieta BJ. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Sys Rev 2001;1:CD000147.

    Google Scholar 

  25. Görtelmeyer R, Erbler H. Memantine in treatment of mild to moderate dementia syndrome. Drug Res 1992;42:904–912.

    Google Scholar 

  26. Winblad B, Poritis N. Clinical improvement in a placebo-controlled trial with memantine in care-dependent patients with severe dementia [abstract]. Neurobiol Aging 1998;19(Suppl):S303.

    Google Scholar 

  27. Wilcock G, Möbius HJ, Stoffler A, on behalf of the MMM 500 group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Intl Clin Psychopharmacol 2002;17:297–305.

    Google Scholar 

  28. Möbius HJ, Stöffler A. Memantine in vascular dementia. Intl Psychogeriatrics 2003;15(Suppl l):207–213.

    Article  Google Scholar 

  29. Möbius HJ, Stöffler A. New approaches to clinical trials in vascular dementia: Memantine in small vessel disease. Cerebrovasc Dis 2002;13(Suppl 2):61–66.

    PubMed  Google Scholar 

  30. Vinters HV, Ellis WG, Zarow C, et al. Neuropathologic substrates of ischemic vascular dementia. J Neuropathol Exp Neurol 2000;60:658–659.

    Google Scholar 

  31. Selden NR, Gitelman DR, Salamon-Murayama N, Parrsh TB, Mesulam MM. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 1998;121:2249–2257.

    Article  PubMed  Google Scholar 

  32. Mesulam M, Siddique T, Cohen B. Cholinergic denervation in a pure multi-infarct state: observations on CADASIL. Neurology 2003;60:1183–1185.

    PubMed  Google Scholar 

  33. Togashi H, Matsumoto K, Yoshida M. Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rat. Neurosci Lett 1994;166:117–120.

    Article  PubMed  CAS  Google Scholar 

  34. Freidle RL. A comparative histochemical mapping of the distribution of butyrylcholinesterase in the brains of four species of animals, including man. Acta Anat (Basel) 1967;66:161–177.

    Google Scholar 

  35. Court JA, Perry EK, Kalaria RN. Neurotransmitter control of the cerebral vasculature and abnormalities in vascular dementia. In: Erkinjuntti T, Gauthier S, eds. Vascular Cognitive Impairment. London, UK: Martin Duniz Ltd., 2002, pp. 167–185.

    Google Scholar 

  36. Winblad B, Brodaty H, Gauthier S, et al. Pharmacotherapy of Alzheimer’s disease: is there a need to redefine treatment success? Intl J Geriatr Psychiatry 2001;16:388–390.

    Google Scholar 

  37. Pratt RD, Perdomo CA, the Donepezil VaD 307 and 308 Study Groups. Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits. Ann N Y Acad Sci 2002;977:513–522.

    Article  PubMed  CAS  Google Scholar 

  38. Black S, Roman GC, Geldmacher DS, et al. Efficacy and tolerability of Donepezil in vascular dementia. Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003;34:2323–2332.

    Article  PubMed  CAS  Google Scholar 

  39. Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia. A randomized, placebo-controlled study. Neurology 2003;61:479–486.

    PubMed  CAS  Google Scholar 

  40. Erkinjunti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Chandrasekharrao VD. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. J Am Ger Soc 2002;359:1283–1290.

    Google Scholar 

  41. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.

    PubMed  CAS  Google Scholar 

  42. Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, Damaraju CV. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther 2003;25:1765–1782.

    Article  PubMed  CAS  Google Scholar 

  43. Small G, Erkinjuntti T, Kurz A, Lilienfeld S. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer’s disease with cerebrovascular disease. CNS Drugs 2003;17:905–914.

    Article  PubMed  CAS  Google Scholar 

  44. Erkinjuntti T. Cognitive decline and treatment options for patients with vascular dementia. Acta Neurologica Scand 2002;106(Suppl 178):15–18.

    Article  Google Scholar 

  45. Kurz AF, Erkinjuntti T, Small GW, Lilienfeld S, Damarju CV. Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer’s disease with cerebrovascular disease. Eur J Neurol 2003;10:663.

    Article  Google Scholar 

  46. Moretti R, Torre P, Antonello RM, Cazzato G. Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up. Eur J Neurol 2001;8:361–362.

    Article  PubMed  CAS  Google Scholar 

  47. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci 2002;203:141–146.

    Article  PubMed  Google Scholar 

  48. Kumar V, Anand R, Messian J. An efficacy and safety analysis of Exelon in Alzheimer’s disease with concurrent vascular risk factors. Eur J Neurol 2000;7:159–169.

    Article  PubMed  CAS  Google Scholar 

  49. Erkinjuntti T, Skoog I, Lane R, Andrews C. Rivastigmine in patients with Alzheimer’s disease and concurrent hypertension. Intl J Clin Pract 2002;56:791–796.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Memory Research Unit, Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland

    Timo Erkinjuntti MD

  2. Geriatric Research Education and Clinical Center, Department of Neurology, University of Texas Health Science Center at San Antonio, USA

    Gustavo Román MD

  3. MCSA Alzheimer’s Disease Research Unity, McGill Center for Studies on Aging, McGill University, Montreal, Canada

    Serge Gauthier MD

  4. Geriatric Medicine Research Unit, Queen Elizabeth II Health Science Center, Dalhousie University, Halifax, Nova Scotia, Canada

    Kenneth Rockwood PhD

Authors
  1. Timo Erkinjuntti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gustavo Román MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Serge Gauthier MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenneth Rockwood PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Psychiatry and Human Behavior, Brown Medical School, Providence, RI

    Robert H. Paul PhD  & Ronald Cohen PhD  & 

  2. Department of Neurology, Memorial Hospital of Rhode Island, Pawtucket, Rhode Island

    Brian R. Ott MD

  3. Department of Clinical Neurosciences, Brown Medical School, Providence, RI

    Brian R. Ott MD  & Stephen Salloway MD  & 

  4. Department of Neurology, Butler Hospital, USA

    Stephen Salloway MD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Erkinjuntti, T., Román, G., Gauthier, S., Rockwood, K. (2005). Pharmacological Treatment of Vascular Dementia. In: Paul, R.H., Cohen, R., Ott, B.R., Salloway, S. (eds) Vascular Dementia. Current Clinical Neurology. Humana Press. https://doi.org/10.1385/1-59259-824-2:297

Download citation

  • DOI: https://doi.org/10.1385/1-59259-824-2:297

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-366-4

  • Online ISBN: 978-1-59259-824-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation